TECTONIC THERAPEUTIC, INC. (TECX) Free cash flow
- Free cash flow · 12 months (USD): Value $-72.42M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-72.42M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-72.14M − $279.00K ≈ $-72.42M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-72.14M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.00× | Operating cash flow / net income. Period ending 2026-06-30. $-72.14M ÷ $-74.16B ≈ 0.00× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -72.14M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 279.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -72.42M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -74.16B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-72.42M | (m) | $-72.14M | $279.00K | (m) | (m) | (m) | $-74.16B | (m) | (m) | (m) | 0.00× |
| 2026-03-31 | $-65.61M | (m) | $-65.41M | $200.00K | (m) | (m) | (m) | $-74.16B | (m) | (m) | (m) | 0.00× |
| 2025-12-31 | $-60.29M | (m) | $-60.08M | $208.00K | (m) | (m) | (m) | $-74.15M | (m) | (m) | (m) | 0.81× |
| 2025-09-30 | $-62.65M | (m) | $-62.44M | $211.00K | (m) | (m) | (m) | $-67.30M | (m) | (m) | (m) | 0.93× |
| 2025-06-30 | $-64.41M | (m) | $-64.23M | $183.00K | (m) | (m) | (m) | $-65.98M | (m) | (m) | (m) | 0.97× |
| 2025-03-31 | $-63.07M | (m) | $-62.89M | $179.00K | (m) | (m) | (m) | $-58.67M | (m) | (m) | (m) | 1.07× |
| 2024-12-31 | $-59.24M | (m) | $-59.08M | $156.00K | (m) | (m) | (m) | $-57.98M | (m) | (m) | (m) | 1.02× |
| 2024-09-30 | $-76.36M | (m) | $-76.42M | $-68.00K | (m) | (m) | (m) | $1.50M | (m) | (m) | (m) | -50.88× |
| 2024-06-30 | $-65.09M | (m) | $-65.30M | $-214.00K | (m) | (m) | (m) | $9.16M | (m) | (m) | (m) | -7.13× |
| 2024-03-31 | $-50.48M | (m) | $-50.48M | $0.00 | (m) | (m) | (m) | $30.31M | (m) | (m) | (m) | -1.67× |
| 2023-12-31 | $-63.20M | (m) | $-63.19M | $8.00K | (m) | (m) | (m) | $12.16M | (m) | (m) | (m) | -5.20× |
| 2023-09-30 | $-78.84M | (m) | $-78.83M | $8.00K | (m) | (m) | (m) | $-4.09M | (m) | (m) | (m) | 19.26× |
| 2023-06-30 | $-75.12M | (m) | $-75.02M | $94.00K | (m) | (m) | (m) | $-5.48M | (m) | (m) | (m) | 13.68× |
| 2023-03-31 | $-89.72M | (m) | $-89.48M | $243.00K | (m) | (m) | (m) | $-101.01M | (m) | (m) | (m) | 0.89× |
| 2022-12-31 | $-97.47M | (m) | $-97.21M | $267.00K | (m) | (m) | (m) | $-105.89M | (m) | (m) | (m) | 0.92× |
| 2022-09-30 | $-100.55M | (m) | $-99.43M | $1.12M | (m) | (m) | (m) | $-109.08M | (m) | (m) | (m) | 0.91× |
| 2022-06-30 | $-109.14M | (m) | $-107.84M | $1.30M | (m) | (m) | (m) | $-118.73M | (m) | (m) | (m) | 0.91× |
| 2022-03-31 | $-101.08M | (m) | $-98.70M | $2.38M | (m) | (m) | (m) | $-122.06M | (m) | (m) | (m) | 0.81× |
| 2021-12-31 | $-100.49M | (m) | $-98.03M | $2.46M | (m) | (m) | (m) | $-119.13M | (m) | (m) | (m) | 0.82× |
| 2021-09-30 | $-104.31M | (m) | $-102.62M | $1.69M | (m) | (m) | (m) | $-119.03M | (m) | (m) | (m) | 0.86× |
| 2021-06-30 | $-104.11M | (m) | $-102.66M | $1.46M | (m) | (m) | (m) | $-123.20M | (m) | (m) | (m) | 0.83× |
| 2021-03-31 | $-104.42M | (m) | $-103.71M | $715.00K | (m) | (m) | (m) | $-120.64M | (m) | (m) | (m) | 0.86× |
| 2020-12-31 | $-99.98M | (m) | $-98.80M | $1.18M | (m) | (m) | (m) | $-119.71M | (m) | (m) | (m) | 0.83× |
| 2020-09-30 | $-88.76M | (m) | $-86.90M | $1.86M | (m) | (m) | (m) | $-114.24M | (m) | (m) | (m) | 0.76× |
| 2020-06-30 | $-77.33M | (m) | $-75.42M | $1.91M | (m) | (m) | (m) | $-94.61M | (m) | (m) | (m) | 0.80× |
| 2020-03-31 | $-74.19M | (m) | $-72.36M | $1.82M | (m) | (m) | (m) | $-81.83M | (m) | (m) | (m) | 0.88× |
| 2019-12-31 | $-69.25M | (m) | $-67.67M | $1.58M | (m) | (m) | (m) | $-72.97M | (m) | (m) | (m) | 0.93× |
| 2019-09-30 | $-61.83M | (m) | $-60.52M | $1.31M | (m) | (m) | (m) | $-66.32M | (m) | (m) | (m) | 0.91× |
| 2019-06-30 | $-61.27M | (m) | $-59.12M | $2.15M | (m) | (m) | (m) | $-60.77M | (m) | (m) | (m) | 0.97× |
| 2019-03-31 | $-51.31M | (m) | $-49.41M | $1.91M | (m) | (m) | (m) | $-55.22M | (m) | (m) | (m) | 0.89× |
| 2018-12-31 | $-39.48M | (m) | $-37.65M | $1.83M | (m) | (m) | (m) | $-46.36M | (m) | (m) | (m) | 0.81× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-16.77M | (m) | $-16.38M | $383.00K | (m) | (m) | (m) | $-18.65M | (m) | (m) | (m) | 0.88× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |